Join Barchart Premier to attend LIVE "Market on Close" program each Friday with John Rowland. FREE 30 Day Trial
or

Kineta Inc (KANT)

Kineta Inc (KANT)
N/A x N/A N/A x N/A
Pre-market by (Cboe BZX)
0.3861 -0.0098 (-2.48%) 01/21/25 [OTC US]
N/A x N/A N/A x N/A
Pre-market 0.3861 unch (unch) 14:43 ET
Quote Overview for Tue, Jan 21st, 2025
Watch
    Add or delete the symbol from one or more Watchlists.
Day Low
0.3801
Day High
0.4001
Open 0.4001
Previous Close 0.3959 0.3959
Volume 1,600 1,600
Avg Vol 12,265 12,265
Stochastic %K 36.00% 36.00%
Weighted Alpha N/A N/A
5-Day Change -0.0439 (-10.21%) -0.0439 (-10.21%)
52-Week Range 0.2600 - 1.1500 0.2600 - 1.1500
  • 1D
  • 5D
  • 1M
  • 3M
  • 6M
  • 1Y
  • 5Y
  • MAX
Full Chart
  • OHLC Bars
  • Colored OHLC Bars
  • HLC Bars
  • Candlestick Hollow
  • Candlestick Open-to-Close
  • Candlestick Close-to-Close
  • Heikin-Ashi
  • Line Chart
  • Area Chart
  • Renko
  • Column
  • Baseline
  • Line Break
  • Range
  • Kagi
  • Point And Figure

Fundamentals

See More
  • Market Capitalization, $K 8,416
  • Shares Outstanding, K 12,250
  • Annual Sales, $ 5,440 K
  • Annual Income, $ -14,100 K
  • EBIT $ -17 M
  • EBITDA $ -17 M
  • 60-Month Beta 0.46
  • Price/Sales 1.55
  • Price/Cash Flow N/A
  • Price/Book N/A
  • Price/Earnings ttm 0.00
  • Earnings Per Share ttm -1.74
  • Most Recent Earnings $-0.20 on 08/08/24
  • Next Earnings Date 11/01/24
  • Annual Dividend & Yield N/A (0.00%)
  • Most Recent Dividend N/A on N/A
  • Sectors:

Price Performance

See More
Period Period Low Period High Performance
1-Month
0.3435 +12.40%
on 01/06/25
Period Open: 0.4123
0.4800 -19.56%
on 01/08/25
-0.0262 (-6.35%)
since 12/20/24

Most Recent Stories

More News
TuHURA Biosciences, Inc. Enters into Definitive Merger Agreement to Acquire Kineta, Inc.

Opportunistic acquisition adds Phase 2 novel checkpoint inhibitor (KVA12123) to TuHURA's late stage pipeline

HURA : 4.82 (+1.36%)
KANT : 0.3861 (-2.48%)
TuHURA Biosciences, Inc. (Nasdaq: HURA) Outlines Development Pathway for Single Phase 3 Accelerated Approval Registration Trial in First Line Treatment of Advanced or Metastatic Merkel Cell Carcinoma and Provides Business Update

IFx-2.0, a first-in-class innate immune response agonist, entering single Phase 3 accelerated approval registration trial in first half of 2025 for first line treatment of Merkel Cell Carcinoma (MCC) under...

HURA : 4.82 (+1.36%)
KANT : 0.3861 (-2.48%)
Kineta Updates KVA12123 Clinical Results from Ongoing Phase 1/2 VISTA101 Study at Society for Immunotherapy of Cancer (2024)

KANT : 0.3861 (-2.48%)
Kineta Announces Completion of Enrollment in the Monotherapy Arm of the VISTA-101 Phase 1 Clinical Study in Advanced Solid Tumors

KA : 0.5746 (-30.69%)
KANT : 0.3861 (-2.48%)
Kineta Announces KVA12123 Abstract Accepted for Poster Presentation at Society for Immunotherapy of Cancer (SITC) 2024

KA : 0.5746 (-30.69%)
KANT : 0.3861 (-2.48%)

Business Summary

Kineta, Inc. is a clinical-stage biotechnology company. It develops next-generation immunotherapies that address the major challenges with current cancer therapy. The company's lead asset is KVA12123, a novel VISTA blocking immunotherapy. Kineta merged with Yumanity Therapeutics, Inc., and is based...

See More

Key Turning Points

3rd Resistance Point 0.4174
2nd Resistance Point 0.4088
1st Resistance Point 0.3974
Last Price 0.3861
1st Support Level 0.3774
2nd Support Level 0.3688
3rd Support Level 0.3574

See More

52-Week High 1.1500
Fibonacci 61.8% 0.8100
Fibonacci 50% 0.7050
Fibonacci 38.2% 0.6000
Last Price 0.3861
52-Week Low 0.2600

See More

Want to use this as
your default charts setting?
Save this setup as a Chart Templates
Switch the Market flag
for targeted data from your country of choice.
Open the menu and switch the
Market flag for targeted data from your country of choice.
Want Streaming Chart Updates?
Switch your Site Preferences
to use Interactive Charts
Need More Chart Options?
Right-click on the chart to open the Interactive Chart menu.
Use your up/down arrows to move through the symbols.

Free Barchart Webinar

Master Swing Trading: Strategies for Momentum and Trends